Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth
Company Announcements

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

Kiromic Biopharma (KRBP) has released an update.

Kiromic BioPharma, Inc. has secured a financial boost by issuing a Senior Secured Convertible Promissory Note worth $2 million to an accredited investor, carrying a substantial 25% annual interest rate. This note will mature in a year, with the option for the investor to convert the debt into company stock at a set price, subject to ownership limits. The debt, secured by the company’s assets and intellectual property, is prioritized over other obligations and allows for additional borrowing, signaling a strategic move to strengthen the company’s financial position amidst its growth trajectory.

For further insights into KRBP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyKiromic BioPharma’s Deltacel receives FDA fast track designation
TheFlyKiromic BioPharma reports interim results from Deltacel-01 trial
TipRanks Auto-Generated NewsdeskKiromic BioPharma’s Strategic Financial Restructuring and Equity Shift
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App